TITOMIC (ASX:TTT) $1.7- 4.6%
TITOMIC (ASX:TTT) $1.7- 4.6%
TITOMIC (ASX:TTT) $1.7- 4.6%
Stock positions of major stocks at 15:00 - Tuesday 6th August 2019
Stock positions of major stocks at 15:00 - Tuesday 6th August 2019
AFTERPAY TOUCH (ASX:APT) $22.31 - 5.6%
ALTIUM (ASX:ALU) $31.68 - 5.2%
LIVETILES (ASX:LVT) $0.41 - 4.6%
NEARMAP (ASX:NEA) $3.02- 0.33%
TITOMIC (ASX:TTT) $1.7- 4.6%
AFTERPAY TOUCH (ASX:APT) $22.31 - 5.6%
ALTIUM (ASX:ALU) $31.68 - 5.2%
LIVETILES (ASX:LVT) $0.41 - 4.6%
NEARMAP (ASX:NEA) $3.02- 0.33%
TITOMIC (ASX:TTT) $1.7- 4.6%
This library contains Conversations conducted prior to the upgrading of our site in July 2020. Simply search by company name to find what you're after.
Updated: Jun 15, 2020
Is this little aussie tech company the next Cochlear?
CEO Philip Daffas explains to InsideMarket.net how and why he believes it could track the same way.
Daffas is the former VP of Marketing at CochlearGlobal Marketing Manager Roche and now CEO of Painchek (ASX:EPT)
![PainChek [ASX:PCK] is exploring a new use in a COVID world.](https://static.wixstatic.com/media/03d3b8_8bda94550e5e46ccb0ad37298f5d3d1d~mv2.jpg/v1/fill/w_980,h_651,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/03d3b8_8bda94550e5e46ccb0ad37298f5d3d1d~mv2.jpg)
Comments